Trial shows efficacy of Xeplion in Schizophrenia- Janssen Pharma

New data shows flexible maintenance dosing with Xeplion (paliperidone palmitate), from Janssen Pharmaceuticals, was associated with a clinically relevant treatment response, and was well tolerated in both acute and non-acute patients with Schizophrenia. The study, called PALMFlexS, is a prospective 6-month, open-label study investigating the efficacy, safety and tolerability of Xeplion in a population which much more closely resembles day-to-day clinical practice than those included in published pivotal trials, as patients included in this trial had higher rates of comorbidities, substance abuse and/or co-medications.

The data showed that treatment with monthly Xeplion in recently diagnosed non-acute Schizophrenia patients (less than 3 years) consistently gave greater clinically relevant responses and lower disease severity, compared with chronic Schizophrenia patients (more than 3 years) at the study endpoint. Results were presented at the German Society for Psychiatry and Psychotherapy, Psychosomatic Medicine and Neurology (DGPPN) congress.